Richard A. Sandberg Acquires 1,399 Shares of Precipio, Inc. (NASDAQ:PRPO) Stock

Precipio, Inc. (NASDAQ:PRPO) Director Richard A. Sandberg purchased 1,399 shares of the company’s stock in a transaction that occurred on Friday, May 30th. The shares were purchased at an average price of $10.00 per share, for a total transaction of $13,990.00. Following the purchase, the director now directly owns 40,175 shares in the company, valued at $401,750. The trade was a 3.61% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Precipio Trading Down 0.6%

NASDAQ:PRPO opened at $9.90 on Monday. The stock’s 50 day moving average price is $6.76 and its 200 day moving average price is $6.59. The company has a market capitalization of $14.97 million, a PE ratio of -5.41 and a beta of 1.12. The company has a quick ratio of 0.60, a current ratio of 0.73 and a debt-to-equity ratio of 0.02. Precipio, Inc. has a 52-week low of $3.90 and a 52-week high of $10.74.

Precipio (NASDAQ:PRPO) last released its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter. The firm had revenue of $4.93 million for the quarter. Precipio had a negative return on equity of 34.01% and a negative net margin of 17.23%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Precipio stock. Renaissance Technologies LLC bought a new stake in Precipio, Inc. (NASDAQ:PRPO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 10,100 shares of the biotechnology company’s stock, valued at approximately $56,000. Renaissance Technologies LLC owned about 0.68% of Precipio at the end of the most recent quarter. Institutional investors own 10.45% of the company’s stock.

About Precipio

Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.